Literature DB >> 1359504

A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.

G Van den Brink1, C W Bollen, O E Van de Wall, L J Hoeve, A J Porsius.   

Abstract

This study presents the results of an analysis of the pharmacy records of 778 patients with asthma or chronic obstructive lung diseases. The high percentage of patients taking oral corticosteroids was striking. Inhaled beta-agonists for use as needed have been prescribed to only a minority of patients using these agents. Only half of the patients on beta-agonists used inhaled corticosteroids prophylactically. Drug interactions capable of causing changes in plasma theophylline concentrations appeared in only a small number of patients. The results from studies like the one presented here can provide valuable data to be used for further discussion between physicians and pharmacists about rational drug therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359504     DOI: 10.1007/bf01977619

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  17 in total

Review 1.  A new approach to the treatment of asthma.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

Review 2.  Difficult asthma.

Authors:  P J Barnes; K F Chung
Journal:  BMJ       Date:  1989-09-16

3.  Steroids and "steroid-sparing" agents in asthma.

Authors:  G R Cott; R M Cherniack
Journal:  N Engl J Med       Date:  1988-03-10       Impact factor: 91.245

4.  Improving the care of asthmatic patients in general practice.

Authors:  M Modell; J M Harding; E J Horder; P R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

5.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.

Authors:  T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

Review 6.  Theophylline in the management of airflow obstruction. 1. Much evidence suggests that theophylline is valuable.

Authors:  G J Addis
Journal:  BMJ       Date:  1990-04-07

7.  Impact of beta 1 selectivity and intrinsic sympathomimetic activity on potential unwanted noncardiovascular effects of beta blockers.

Authors:  M J Kendall
Journal:  Am J Cardiol       Date:  1987-05-15       Impact factor: 2.778

8.  Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD. Comparison with cimetidine and placebo.

Authors:  P Verdiani; S Di Carlo; A Baronti
Journal:  Chest       Date:  1988-10       Impact factor: 9.410

9.  Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.

Authors:  W Boehning
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Regular inhaled beta-agonist treatment in bronchial asthma.

Authors:  M R Sears; D R Taylor; C G Print; D C Lake; Q Q Li; E M Flannery; D M Yates; M K Lucas; G P Herbison
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

View more
  3 in total

Review 1.  Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England.

Authors:  D N Bateman; M Eccles; M Campbell; J Soutter; S J Roberts; J M Smith
Journal:  Br J Gen Pract       Date:  1996-01       Impact factor: 5.386

Review 2.  Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.

Authors:  R Davis; D McTavish
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

3.  The use of hypoglycaemic and cardiovascular drugs in 582 patients with diabetes mellitus. Description and quality assessment.

Authors:  G Van den Brink; R R Schwartzenberg; L J Hoeve; A J Porsius; L L Hoeve
Journal:  Pharm World Sci       Date:  1993-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.